Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative and metabolic disorders, has signed a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement the Phase 2 trial of Lucid-MS, its lead drug candidate for multiple sclerosis (MS). The agreement moves Lucid-MS from planning into execution, following the U.S. Food and Drug Administration's clearance of its Investigational New Drug application in August. This partnership is significant because it pairs Quantum's innovative approach with a leading global contract research organization (CRO) that has deep expertise in central nervous system (CNS) and MS studies, potentially accelerating the development of a first-in-class treatment for progressive MS, where treatment options are limited.
MS affects an estimated 3 million people worldwide, including nearly 1 million in the United States. The disease damages myelin, the protective coating around nerve fibers, leading to disability. A 2023 study in Neurology and Therapy described treatment options for progressive MS as limited, with many patients remaining untreated or continuing to decline despite available therapies. A National MS Society report released this year, drawing on survey responses from more than 2,800 people living with MS, identified urgent unmet needs, including effective treatment of disease progression and therapies that repair myelin damage. This underscores the importance of Quantum's novel approach.
Quantum BioPharma (NASDAQ: QNTM) is focused on developing therapies that target demyelination rather than solely modulating the immune system. Lucid-MS is an investigational, first-in-class new chemical entity that targets peptidyl arginine deiminase 2 (PAD2), an enzyme implicated in the hypercitrullination of myelin proteins. By inhibiting PAD2, Lucid-MS aims to protect the integrity of the myelin sheath. In preclinical models, the compound has demonstrated the ability to prevent and reverse measures of myelin degradation, and it has shown a favorable safety profile in Phase 1 trials in healthy participants.
Thermo Fisher's clinical research business, which the company acquired in 2021 for $17.4 billion, is a leading global CRO with extensive experience in CNS and MS trials. "We're proud to partner with Quantum BioPharma in advancing their neuro-degenerative clinical program in multiple sclerosis," said Michael Cioffi, vice president and general manager, neuroscience, clinical research, at Thermo Fisher. "Our team brings deep experience in CNS and MS trials, along with an integrated approach that connects strategy and execution to help deliver these complex studies."
The Phase 2 trial will be a randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of Lucid-MS in people with progressive MS. It is designed to assess clinical and radiological endpoints tied to disease progression. Quantum BioPharma CEO Zeeshan Saeed stated, "Following FDA clearance to proceed with the phase 2 study, initiating study start-up activities with a leading global CRO with extensive CNS and MS experience represents an important next step." The company has not yet announced enrollment dates or trial sites.
The commercial stakes are notable. Quantum's announcement cites Grand View Research in projecting that the MS therapeutics market will exceed $38 billion by 2030. With this agreement, Quantum BioPharma gains an experienced partner to navigate the complexities of a Phase 2 trial in progressive MS. For more information, visit www.QuantumBioPharma.com. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
This development matters because it represents a critical step forward for a treatment that could address the significant unmet needs in progressive MS. By targeting the underlying myelin damage rather than just modulating the immune system, Lucid-MS offers a novel mechanism that may complement or surpass existing therapies. The partnership with Thermo Fisher provides the operational expertise needed to execute a rigorous clinical test, bringing hope to patients who currently have few options. As the trial progresses, it will be closely watched by investors and the MS community alike.
